By Deanna Neff HealthDay ReporterFRIDAY, Aug. 22, 2025 (HealthDay News) — Families with a child receiving treatment for ...

Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

A statistical analysis (MAIC) of the ARCHES and ARANOTE studies suggests enzalutamide is more effective at delaying disease ...

Researchers have launched HTGAnalyzer, a new, easy-to-use, fast and reproducible bioinformatics tool for advanced transcriptomic data analysis. Designed within the R statistical environment, this ...

The Barcelona Institute for Global Health (ISGlobal), a centre supported by the ”la Caixa” Foundation, has launched HTGAnalyzer, a new, easy-to-use, fast and reproducible bioinformatics tool for ...

But the range of estimated effects is gobsmacking. It fits with my own experience that lots of small differences in the analysis workflow can add to large variation [in results].